<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936802</url>
  </required_header>
  <id_info>
    <org_study_id>Trialign study</org_study_id>
    <nct_id>NCT04936802</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign)</brief_title>
  <official_title>Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign) for the Treatment or Reduction of Moderate to Severe Functional Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate safety and feasibility of the transcatheter&#xD;
      tricuspid valve repair system (Trialign) for the treatment or reduction of moderate to severe&#xD;
      functional tricuspid regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective single-arm trial for transcatheter tricuspid valve repair system&#xD;
      (Trialign). A series of physical, imaging and laboratory exams will be performed to determine&#xD;
      whether a subject has moderate to severe tricuspid regurgitation with high surgical risk.&#xD;
      Subjects who meet the criteria will then receiveTrialign treatment if an informed consent is&#xD;
      obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Tricuspid valve repair</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe adverse device events (SADE)</measure>
    <time_frame>30 days</time_frame>
    <description>Severe adverse device events (SADE) , defined as any device related complication, including but not limited to: death, myocardial infarction, stroke, reoperation, renal failure, pulmonary embolism, gastrointestinal bleeding, readmission, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>30 days</time_frame>
    <description>Technical success, defined as freedom from death with:&#xD;
Successful access, delivery and retrieval of the device delivery system;&#xD;
Deployment and correct positioning of the intended device(s) which is maintained and;&#xD;
No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tricuspid valve function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) classification</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test (6MWT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions questionnaire (EQ-5D)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Transcatheter tricuspid valve repair system (Trialign)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received transcatheter tricuspid valve repair with Trialign will be included in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter tricuspid valve repair system (Trialign)</intervention_name>
    <description>To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation</description>
    <arm_group_label>Transcatheter tricuspid valve repair system (Trialign)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects has been informed the study and provided written informed consent.&#xD;
&#xD;
          2. Age ≥ 18 and ≤ 85 years old.&#xD;
&#xD;
          3. NYHA class II, III or ambulatory IV.&#xD;
&#xD;
          4. The subject was diagnosed moderate to severe functional tricuspid regurgitation&#xD;
&#xD;
          5. The subject was at high risk for open heart valve surgery. The heart team recommended&#xD;
             tricuspid annuloplasty.&#xD;
&#xD;
          6. Subjects shall meet all selected criteria for TEE with moderate or severe tricuspid&#xD;
             regurgitation.&#xD;
&#xD;
               1. Systolic pulmonary artery pressure (SPAP) ≤ 60mmHg.&#xD;
&#xD;
               2. Left ventricular ejection fraction (LVEF) ≥ 30%.&#xD;
&#xD;
               3. Right ventricle tricuspid annular plane systolic excursion (TAPSE) ≥ 15 mm.&#xD;
&#xD;
               4. Tricuspid valve annular diameter ≤ 55 mm.&#xD;
&#xD;
               5. Tricuspid EROA ≤ 1.75 cm2.&#xD;
&#xD;
               6. Functional tricuspid valve regurgitation pathology with a structurally normal&#xD;
                  valve.&#xD;
&#xD;
          7. Sufficient posterior annular dimension for device implantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg).&#xD;
&#xD;
          2. History of heart transplant.&#xD;
&#xD;
          3. Previous tricuspid valve repair or replacement (including artificial valve).&#xD;
&#xD;
          4. Presence of a left ventricular assist device.&#xD;
&#xD;
          5. Active endocarditis.&#xD;
&#xD;
          6. Severe degenerative tricuspid valve disease.&#xD;
&#xD;
          7. Severe aortic stenosis.&#xD;
&#xD;
          8. The degree of mitral regurgitation is greater than grade 3.&#xD;
&#xD;
          9. Complete occlusion due to chronic calcification of the right coronary artery.&#xD;
&#xD;
         10. History of right internal jugular vein occlusion or thrombosis;&#xD;
&#xD;
         11. Anatomy in the region of the access path (right internal jugular vein) prevented&#xD;
             correct placement of a percutaneous tricuspid valve annuloplasty system (e.g.: the&#xD;
             presence of spinal stenosis, stent, vascular prosthesis).&#xD;
&#xD;
         12. An indication of the presence of thrombi in the right ventricle or atrium.&#xD;
&#xD;
         13. Myocardial infarction (MI) or known unstable angina within the 30 days prior to the&#xD;
             index procedure.&#xD;
&#xD;
         14. Any percutaneous coronary intervention (PCI) within 30 days prior to the index&#xD;
             procedure or planned 3 months post-the index procedure.&#xD;
&#xD;
         15. Hemodynamic instability or cardiogenic shock.&#xD;
&#xD;
         16. Restrictive or hypertrophic cardiomyopathy. Constructive pericarditis, or other&#xD;
             structural heart disease.&#xD;
&#xD;
         17. Cerebrovascular accident (CVA) within the past 6 months&#xD;
&#xD;
         18. Serum creatinine &gt; 2.5 mg/dL (or 221 μmol/L), Impaired kidney function, defined as&#xD;
             glomerular filtration rate (GFR) of 30 mL/min or less.&#xD;
&#xD;
         19. Anemia (hemoglobin &lt;&lt;90g/L) not corrected by transfusion. Thrombocytopenia (platelet&#xD;
             count &lt;100×109/L) or thrombocytosis (&gt;750×109/L).&#xD;
&#xD;
         20. Bleeding disorders or hypercoagulable state.&#xD;
&#xD;
         21. Active peptic ulcer or active gastrointestinal bleeding.&#xD;
&#xD;
         22. Contraindication to anticoagulant or antiplatelet therapies.&#xD;
&#xD;
         23. Contraindications to or refusal of blood transfusions.&#xD;
&#xD;
         24. Known allergy to stainless steel, nickel, platinum iridium, polyester and/or silk.&#xD;
&#xD;
         25. Pregnant or lactating; or female of childbearing potential with a positive pregnancy&#xD;
             test 24 hours before any study-related radiation exposure.&#xD;
&#xD;
         26. Life expectancy less than 12 months.&#xD;
&#xD;
         27. Concurrent use of another clinical study product or use of another clinical study&#xD;
             product within 30 days prior to enrolment.&#xD;
&#xD;
         28. Other circumstances deemed unsuitable for inclusion by the researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Tao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Wang</last_name>
    <phone>86-18092798759</phone>
    <email>trialign@163.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

